Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 26;10(8):1183.
doi: 10.3390/vaccines10081183.

Factors Associated with Not Receiving a Booster Dose of COVID-19 Vaccine in Peru

Guido Bendezu-Quispe  1 , Brenda Caira-Chuquineyra  2 , Daniel Fernandez-Guzman  3 , Diego Urrunaga-Pastor  4 , Percy Herrera-Añazco  5   6   7 , Vicente A Benites-Zapata  5   8
Affiliations

Factors Associated with Not Receiving a Booster Dose of COVID-19 Vaccine in Peru

Guido Bendezu-Quispe et al. Vaccines (Basel). .

Abstract

To determine the factors associated with not receiving the booster dose for COVID-19 in Peru, a cross-sectional study by secondary analysis of a University of Maryland and Facebook survey database assessing the global impact of COVID-19 was conducted. Data of Peruvian users of this social network over 18 years of age who answered the survey between 13 February 2022 and 14 April 2022 were analyzed. We evaluated the association between sociodemographic characteristics, comorbidities, and history of COVID-19 with having received a booster dose for COVID-19. Crude (cPR) and adjusted (aPR) prevalence ratios with their respective 95% confidence intervals (95%CI) were calculated. A sample of 20,814 adults, 21.5% of whom reported not receiving the booster dose, was analyzed. People under 75 years of age had a higher prevalence of not having received the booster dose. Likewise, having a university education (aPR = 1.03; 95%CI: 1.02-1.05), secondary, or pre-university education (aPR = 1.07; 95%CI: 1.05-1.09), or having a primary level or less (aPR = 1.11; 95%CI: 1.05-1.18), were associated with a higher prevalence of not receiving the booster, compared to individuals with a postgraduate education. Being employed (aPR = 1.01; 95%CI: 1.00-1.02), having had COVID-19 (aPR = 1.03; 95%CI: 1.01-1.04) and living in a town (aPR = 1.05; 95%CI: 1.02-1.07) or in a rural area (aPR = 1.06; 95%CI: 1.03-1.10), compared to living in the city, had a similar association. On the contrary, the female gender was associated with a lower prevalence of not receiving the booster (aPR = 0.97; 95%CI: 0.96-0.99). Sociodemographic characteristics and a history of having had COVID-19 were associated with the probability of not having received the booster dose for COVID-19 in the Peruvian population.

Keywords: COVID-19; COVID-19 vaccine booster shot; Peru; SARS-CoV-2; vaccination refusal.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flowchart of the selection of participants included in the analysis.
See this image and copyright information in PMC

References

    1. Johns Hopkins University COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) [(accessed on 2 May 2022)]. Available online: https://coronavirus.jhu.edu/map.html.
    1. World Health Organization Vaccines and Immunization. [(accessed on 27 April 2022)]. Available online: https://www.who.int/health-topics/vaccines-and-immunization#tab=tab_1.
    1. Li X., Mukandavire C., Cucunubá Z.M., Londono S.E., Abbas K., Clapham H.E., Jit M., Johnson H.L., Papadopoulos T., Vynnycky E., et al. Estimating the Health Impact of Vaccination against Ten Pathogens in 98 Low-Income and Middle-Income Countries from 2000 to 2030: A Modelling Study. Lancet. 2021;397:398–408. doi: 10.1016/S0140-6736(20)32657-X. - DOI - PMC - PubMed
    1. Watson O.J., Barnsley G., Toor J., Hogan A.B., Winskill P., Ghani A.C. Global Impact of the First Year of COVID-19 Vaccination: A Mathematical Modelling Study. Lancet Infect. Dis. 2022;22:174–175. doi: 10.1016/S1473-3099(22)00320-6. - DOI - PMC - PubMed
    1. Krause P.R., Fleming T.R., Peto R., Longini I.M., Figueroa J.P., Sterne J.A.C., Cravioto A., Rees H., Higgins J.P.T., Boutron I., et al. Considerations in Boosting COVID-19 Vaccine Immune Responses. Lancet. 2021;398:1377–1380. doi: 10.1016/S0140-6736(21)02046-8. - DOI - PMC - PubMed

LinkOut - more resources